L-5-hydroxytryptophan can prevent nociceptive disorders in man

Adv Exp Med Biol. 1999:467:177-82. doi: 10.1007/978-1-4615-4709-9_23.

Abstract

Prevention of primary pain is a new topic, endowed with social and economic interest. We observed that L-5-HTP can induce a significant decrease of the cropping out of migraine, the commonest primary pain. This finding seems interesting, since it represents the first data in the field and was obtained in a prospective, long-term, placebo controlled study. The result obtained suggests that CNS abnormalities underlying the mechanism of migraine can be changed by L-5-HTP, if the amino acid is administered to subjects who are predisposed to headache.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • 5-Hydroxytryptophan / therapeutic use*
  • Analgesics / therapeutic use*
  • Ascorbic Acid / therapeutic use
  • Child
  • Child, Preschool
  • Female
  • Follow-Up Studies
  • Humans
  • Hyperalgesia / physiopathology*
  • Male
  • Migraine Disorders / prevention & control*
  • Pain / prevention & control*
  • Pain Measurement
  • Placebos
  • Prospective Studies
  • Risk Factors
  • Time Factors

Substances

  • Analgesics
  • Placebos
  • 5-Hydroxytryptophan
  • Ascorbic Acid